and left ventricular (LV) hypertrophy (LVH), LV mass indexed to height 2.7 , LV geometry, ejection fraction (EF) and diastolic dysfunction was assessed in 3,483 participants without NYHA class III/IV HF, enrolled in the Chronic Renal Insufficiency Cohort study. Results: The mean estimated glomerular filtration rate was 42.5 ± 17 ml/min/1.73 m 2 . The overall prevalence of LVH was 51.2%, with 57.8, 50.9 and 47.7% for bicarbonate categories <22, 22-26 and >26 mmol/l, respectively. Participants with low bicarbonate were more likely to have LVH and abnormal LV geometry (OR 1.32; 95% CI 1.07-1.64, and OR 1.57; 95% CI 1.14-2.16, respectively). However,
Introduction
Acid-base disturbances are common in patients with chronic kidney disease (CKD) [1] . The kidneys maintain the acid-base equilibrium by excreting acid in amounts that are equal to the extra-renal acid production by reclaiming filtered bicarbonate and regenerating base through the excretion of ammonium and titratable acid [2] . A decline in kidney function leads to impaired generation of new bicarbonate and abnormal or preserved tubular bicarbonate reabsorption resulting in a low-degree chronic metabolic acidosis commonly observed in CKD patients [3, 4] .
Heart failure (HF) is common and associated with high morbidity and mortality in patients with CKD [5] . Also, left ventricular (LV) hypertrophy (LVH) is common in CKD [6] [7] [8] and is an important predictor of long-term adverse outcomes [9, 10] . The role of acid-base abnormalities on cardiac muscle is not completely understood. In animal models, mild renal insufficiency results in early cardiac fibrosis and impaired diastolic function, which progresses to more global LV remodeling and dysfunction [11] . Acutely induced myocardial acidosis adversely affects the recovery of micro-vascular and LV function and increases indices of apoptosis with potential longterm effect on cardiac performance [12] . A low pH has been associated with the reduction of Na+-K+-ATPase activity in myocardial cells [13] , which could lead to reduced myocardial contractility and congestive HF [14] . Whether the low-grade chronic metabolic acidosis associated with CKD plays a role in LV remodeling is unknown.
Our previous work in the Chronic Renal Insufficiency Cohort (CRIC) study showed a 'U-shaped' association between serum bicarbonate and clinical HF events, with an increased risk of HF at both extremes of serum bicarbonate [15, 16] . In another study, the magnitude of change in serum bicarbonate level, regardless of direction, was correlated with increased mortality in a cohort of patients hospitalized for HF [17] . Whether serum bicarbonate levels are associated with cardiac structural or functional abnormalities that predispose to these clinical outcomes is not known.
The goal of this analysis was to evaluate the association between serum bicarbonate levels and LV structure and function, including LV mass and hypertrophy, ejection fraction (EF), measures of diastolic dysfunction and LV geometry in a cohort of patients with CKD.
Methods

Study Design and Population
The CRIC study enrolled 3,943 individuals aged 21-74 with estimated glomerular filtration rate (eGFR) 20 [18] [19] [20] . Major exclusion criteria included prior dialysis treatment lasting >1 month, NYHA Class III/IV HF, polycystic kidney disease, or other primary renal diseases requiring active immunosuppression, human immunodeficiency virus infection, pregnancy, and inability to give informed consent or institutionalization. Participants underwent annual study visits and telephone follow-up twice a year. Echocardiogram evaluation was performed at study years 1, 4 and 7. The study population for this analysis included 3,483 participants after exclusion of 37 with missing serum bicarbonate measurements at study year 1. There was no statistically significant difference between study participants and those excluded from the analyses (online suppl. fig. 1S ; for all online suppl. material, see www.karger.com/doi/10.1159/000446860). Study participants provided written informed consent and are followed annually under protocols approved by Institutional Review Boards at each of the CRIC study clinical centers.
Data Collection
Main Predictor Serum bicarbonate was measured annually using an enzymatic procedure with phosphoenolpyruvate carboxylase on the Ortho Vitros platform at the University of Pennsylvania Core Laboratory. The current analysis examined bicarbonate continuously per 1 mmol/l increase, and categorically using the following groups of serum bicarbonate: <22, 22-26 (reference group) and >26 mmol/l. The cut points for categories of serum bicarbonate used are based on the current recommended clinical guidelines in CKD and available literature [15] .
Outcomes
The study outcomes were 2D mode echocardiography measures of cardiac structure and function. All echocardiograms were read centrally at the University of Pennsylvania by one reader who was blinded to the studies.
LV mass was calculated using the area-length method and indexed to height 2.7 [21] . LVH was defined as LV mass/height 2.7 ≥ 47 g/m 2.7 in women and ≥ 50 g/m 2.7 in men [22, 23] .
Relative wall thickness (RTW) was calculated as 2 times posterior wall thickness/LV internal linear dimension in diastole, and it was considered to be increased if ≥ 0.45. LV mass and RTW were used to categorize LV geometry: normal (normal LV mass and normal RWT), concentric remodeling (normal LV mass and increased RWT), eccentric hypertrophy (increased LV mass and normal RWT), and concentric hypertrophy (increased LV mass and increased RWT).
LV systolic function was assessed using the EF obtained from echocardiograms. LV end-diastolic and end-systolic volumes were calculated using the modified biplane method. EF was calculated as (end-diastolic volume -end-systolic volume)/end-diastolic volume. LV systolic dysfunction was defined as EF <45% [24] .
LV diastolic function was categorized as normal or mildly, moderately, or severely abnormal (corresponding to normal and grades 1, 2, and 3 diastolic dysfunction) based on mitral inflow E-and A-wave velocities, E-wave deceleration time, and pulmonary venous reverse A-wave duration [25] . These parameters were unable to obtain in 564 participants due to equipment limitations of one CRIC center. A small subset (<1%) of participants with atrial fibrillation could not have measurements of diastolic dysfunction.
Covariates Demographic and clinical information were obtained at the baseline and follow-up study visits by questionnaires, interviews and physical examination. History of any cardiovascular disease (CVD) included prior myocardial infarction, revascularization, HF, stroke, or peripheral arterial disease. Current smoking was defined as self-report of current use of cigarettes and at least 100 cigarettes smoked. At each study visit, participants were queried about any medication usage in the prior 30 days. All anti-hypertensive medications were categorized into drug classes, and the total number of anti-hypertensive drug classes was calculated. All hospitalization records were reviewed and clinical events were adjudicated by 2 independent reviewers according to CRIC study protocol. eGFR was calculated using the CRIC study equation [26] .
Diabetes mellitus was defined as a fasting glucose >126 mg/dl, a non-fasting glucose >200 mg/dl, or use of insulin or other antidiabetic medication [27] . Hypertension was defined as systolic blood pressure (BP) ≥ 140 mm Hg, diastolic BP ≥ 90 mm Hg, or use of antihypertensive medications [28] .
Statistical Analysis
The characteristics of study participants were depicted using standard descriptive statistics, overall and stratified by categories of serum bicarbonate <22, 22-26 and >26 mmol/l. Pearson's χ 2 for categorical variables and t test for continuous variables were used to analyze the covariates of interest and their association with serum bicarbonate.
Multivariable linear regression models were used to assess the association between bicarbonate and LV mass, cross-sectional at CRIC study year 1. Secondary longitudinal analyses were performed during follow-up at CRIC study years 4 and 7. To address potential nonlinearity, restricted cubic spline models were created. The goodness of curve fit was assessed with the F test. Logistic regression models were built to assess the association between serum bicarbonate and LVH, LV systolic and diastolic dysfunction, crosssectional at study year 1 and during follow-up at years 4 and 7. Diastolic dysfunction was dichotomized into normal vs. abnormal (corresponding to mildly, moderately and severely abnormal) relaxation. Multinomial logistic regression models were built to assess the 4 categories of LV geometry, using normal geometry as the reference group. The models were adjusted for relevant confounding variables, including demographics (age, gender, race/ethnicity), traditional CVD risk factors (hypertension, diabetes, smoking, low-density lipoprotein cholesterol, prior history of CVD), medications (angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, diuretics, anti-acidosis medications) and kidney function (eGFR and urine protein excretion). Sequential multivariable models for each outcome were created based on our assessment of the likelihood of covariates being a confounder in the relationship between serum bicarbonate and heart disease. All models were also adjusted for study clinical center to account for the potential variability across centers. Residual plots were used to confirm model assumptions.
The effect modification by an a priori selected set of baseline characteristics including race/ethnicity, diabetes status, diuretic use, level of kidney function (eGFR <45 and ≥ 45 ml/min/1.73 m 2 ) and proteinuria was also explored. Because the presence of CVD is correlated closely with recurrence of cardiovascular events, a secondary set of analyses was performed to evaluate the outcomes of interest in participants without known CVD. Additionally, we assessed the subsequent risk of serum bicarbonate to predict LVH in participants without known LVH at study year 1. Similarly, we evaluated the risk conferred by serum bicarbonate on the development of abnormal LV geometry during follow-up in participants with normal LV geometry at study year 1. All statistical tests were 2-sided, and p < 0.05 was considered significant. IBM Corp 
Results
The study cohort included 3,483 participants with a mean age of 58.9 ± 10.8 (SD), mean eGFR of 42.5 ml/ min/1.73 m Unless otherwise noted, values are n (%) or means ± SDs. ACE = Angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; FGF23 = fibroblast growth factor 23; LDL = lowdensity lipoprotein; HDL = high-density lipoprotein.
* p value obtained from 1-way analysis of variance or chi-square as appropriate. # Median (interquartile range). Anti-acidosis medications are represented by: calcium citrate, magnesium citrate, potassium citrate, sodium bicarbonate, sodium lactate, sodium citrate, sodium, acetate, tromethamine, and lactated potassium saline.
$ eGFR was calculated from serum creatinine and cystatin C using a CRIC study equation fig. 1 ). In demographically adjusted models, there was an inverse association between bicarbonate and LV mass, with 0.29 g/m 2 lower LV mass with each 1 mmol/l increase in serum bicarbonate (OR -0.29; 95% CI -0.45 to -0.13; table 2 ). After adjustments for traditional cardiovascular risk factors, the association lost its statistical significance (OR 1.47; 95% CI -1.19 to 4.14). Additional adjustments for renal function and proteinuria did not further influence the association. Exploratory nonlinear modeling revealed lack of statistical significance for a nonlinear relationship between bicarbonate and LV mass (p = 0.13; fig. 2 ).
The prevalence of LVH was 51.2% for the entire cohort, with 57.8, 50.5 and 47.7% for the low, normal and high serum bicarbonate groups respectively. In unadjusted and demographically adjusted models, associations of serum bicarbonate with LVH were significant, with nearly 40% higher risk of LVH for the low serum bicarbonate (<22 mmol/l) group (OR 1.38; 95% CI 1.10-1.72), and almost 20% lower risk of LVH for the Approximately 80% of study participants had abnormal LV geometry: 28.9% (729) concentric remodeling, 14.9% (377) eccentric hypertrophy and 35.8% (905) concentric hypertrophy. The participants in the lowest bicarbonate stratum were more likely to have concentric hypertrophy (40.8%, n = 173) compared to those in the normal (34.7%, n = 501) and high-bicarbonate strata (35.1%, n = 231), χ = 17.06, p = 0.009. After adjustments for demographics, participants in the low-bicarbonate stratum (<22 mmol/l) were 58% more likely to have concentric hypertrophy, when compared to the group of bicarbonate 22-26 mmol/l (OR 1.58; 95% CI 1.12-2.24, p = 0.009; table 2 ). Participants in the high-bicarbonate group were less likely to have abnormal LV geometry, and eccentric hypertrophy, in particular (OR 0.69; 95% CI 0.49-0.96, p = 0.03). However, after multivariable adjustments, there was no statistically significant association between strata of serum bicarbonate and LV geometry ( fig. 3 ) .
Serum Bicarbonate and Functional Cardiac Abnormalities
The majority of participants (88.6%) had preserved EF ( ≥ 45%). The odds of having systolic dysfunction (EF <45%) was similar across serum bicarbonate strata in univariate and multivariable adjusted models. There was no statistically significant association between bicarbonate levels and measures of diastolic dysfunction in multivariable logistic regression models, adjusted for demographics, traditional cardiovascular risk factors and kidney function ( table 3 ) .
Longitudinal Changes in Structural and Functional Cardiac Abnormalities
Echocardiography measurements performed at study year 1 were repeated at subsequent study years 4 and 7 ( table 4 ) . Over time, no statistically significant changes were observed in LV mass or EF, in any of the bicarbonate strata. We examined the strength of association between serum bicarbonate at year 1 and progression to LVH in subsequent years, in the subgroup of participants without LVH at year 1. Serum bicarbonate was not an independent predictor of development of LVH in this subgroup (online suppl. table 1S).
Similarly, we explored the association between serum bicarbonate and LV geometry at study years 4 and 7, after exclusion of participants with abnormal geometry, with similar findings (online suppl. table 2S). 
Subgroup Analyses
We performed a series of a priori defined subgroup analyses; the association between serum bicarbonate level and structural and functional cardiac abnormalities was consistent when stratified by race/ethnicity, diabetes status, proteinuria and eGFR levels (online suppl. table 3S). In other sensitivity analyses, we excluded participants with CVD at study baseline and/or in the first year, prior to first echocardiography evaluation; results were consistent (online suppl. table 4S).
Discussion
CKD is frequently associated with HF and confers the highest risk of mortality and hospitalizations for HF [29] . Mechanisms underlying this association are incompletely understood. In this large cohort of individuals with mild to moderate CKD and without NYHA class III/IV HF, we hypothesized that low serum bicarbonate, a feature of chronic metabolic acidosis observed in CKD, is associated with heart structural and functional abnormalities. We found that LV mass is higher, and LVH and abnormal LV geometry are more common in CKD patients with low serum bicarbonate. However, these associations were attenuated and not statistically significant after adjustment for traditional cardiovascular risk factors and kidney function.
To our knowledge, this is the first study to comprehensively evaluate the association between serum bicarbonate and echocardiographic measures of cardiac structure and function in CKD patients. LV mass was higher, and LVH was more prevalent in participants in the lower serum bicarbonate stratum. Humoral regulatory mechanisms aimed to increase urinary acidification in CKD, including activation of angiotensin II, aldosterone and endothelin can cause direct cardiac damage [30] [31] [32] . The potential link between chronic acidosis in CKD and heart structure abnormalities could be mediated through inflammatory and neurohumoral mechanisms activation. Acidosis and inflammation are strongly linked in CKD [33] [34] [35] . It is reasonable to speculate that the chronic metabolic acidosis results in neurohormonal stimulation and increased inflammatory markers, which could contribute to changes in LV mass and geometry. However, in our study, adjustment for traditional risk factors for heart disease attenuated the association. This suggests that the association between serum bicarbonate and cardiac structure is confounded by the presence of common clinical conditions such as diabetes and hypertension, which may share similar inflammatory and neurohumoral milieu. It is also possible that the association between serum bicarbonate levels and clinical HF episodes is mediated by other factors such as changes in endothelial function and peripheral vascular resistance as discussed below but which are not captured by cardiac imaging.
Animal models described an association between acidosis and myocardial dysfunction. Acute acidemia causes depression of LV function in a dog model [14] and contributes to reduced myocardial contractility in rats with HF [36] . This can be physiologically explained. In order that crossbridges between actin and myosin be created and contraction may occur, the inhibitory action of troponin on actin-myosin interaction must be overcome. In the setting of high intracellular H + , a smaller percentage of the available calcium is able to react with troponin, fewer actin-myosin interactions occur, and the strength of contraction is reduced. Similarly, sarcoplasmic reticulum isolated from heart tissue releases less Ca when the pH of the medium is low. If the results are extrapolated to the intact animal, acute acidosis may cause a lower amount of calcium released during each beat and a subsequent diminished force of contraction [37] .
Few studies have been done in humans to assess the effect of acidosis or alkalosis on the heart. Our previous study in CRIC [15] showed an increased risk of HF episodes both with high and low serum bicarbonate. Some of the symptoms of HF, including weakness and shortness of breath, can be caused by poor oxygen delivery to the peripheral tissues, an action affected by the blood pH. It is reasonable to conceive that at any given increase in blood pH, one would encounter reduced oxygen delivery that would clinically manifest as weakness, shortness of breath, fatigue, without any significant effect on heart structural or functional abnormalities. In human endstage failing myocardium, mild acute acidosis impaired contractility and the b-adrenergic response [38] . However, other studies failed to show a link between acidosis and impaired cardiac function [39] and that debate was solved with the discovery that the direct effect of acute acidosis on the myocardium could be masked by the effect of catecholamines [40, 41] . This might be indeed the rationale behind our previous found link between serum bicarbonate and HF events, but negative association with systolic or diastolic dysfunction. Neurohumoral activation of sympathetic and renin-angiotensin-aldosterone systems induced by chronic acidosis potentially leads to endothelial dysfunction, increase in peripheral venous and arterial resistance, with subsequent increase in preload and afterload, progressive retention of salt and water and edema. However, this hypothesis cannot be directly tested in our current analyses. In addition, the lack of association of serum bicarbonate with systolic dysfunction might not be unexpected, given that patients with NYHA III/IV were excluded from study enrollment and only about 11% had a low EF at study year 1.
This study has the following key strengths: it represents the largest and most comprehensive analyses of the association between serum bicarbonate and cardiac structure and function in CKD. The large and racially diverse patient population, long duration of follow-up, comprehensive covariate measurements, and large subgroup sizes that allow robust subgroup analyses are also important strengths. However, there are important limitations too. Cardiac structure and function measurements were done using 2D mode echocardiography and not cardiac magnetic resonance. LV mass evaluated by cardiac magnetic resonance imaging is more precise and reliable compared to that provided by the 2D mode echocardiography [42, 43] . Furthermore, the ability of 2D mode echocardiography technique to detect serial changes in LV mass measurements may be limited [44, 45] . Therefore, it is possible that the lack of statistical significance in our models may be due to echocardiograms measurement bias. Second, serum bicarbonate alone is not a true estimation of the acid base status, but blood gas analyses were not available in CRIC. We did however adjust the analyses for the presence of lung disease, since some participants might have high bicarbonate as a compensatory mechanism for respiratory acidosis. Third, serum bicarbonate measurements occurred 1-2 days after the original blood draw, and there is a reduction of up to 4 mmol/l in serum bicarbonate concentration for all determinations done 24-48 h from collection; however, this time gap in measurement is common in large epidemiologic studies that use a central laboratory [46] . Lastly, data on valve replacement or cardiac resynchronization therapies that could potentially influence cardiac structure and function were not available; this limited the interpretation of the longitudinal changes in cardiac structure, but not the detailed cross-sectional analyses reported in this paper.
In summary, in this large cohort of patients with CKD, serum bicarbonate was not independently associated with cardiac structural and functional abnormalities. These findings suggest that the association between serum bicarbonate and heart disease are either confounded or mediated by other more traditional cardiovascular risk factors. Other perhaps neurohumoral mechanisms, activated by changes in acid base balance may mediate the association between serum bicarbonate and HF events and merit further studies.
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